

MD Anderson Cancer Center

# Third International Merkel Cell Carcinoma Conference

**REGISTER  
NOW!**

**May 3-4, 2024**

**Houston Marriott Medical Center Hotel**

Houston, Texas 77030

<https://mdanderson.cloud-cme.com/MerkelConf2024>

THE UNIVERSITY OF TEXAS

**MD Anderson  
Cancer Center**

Making Cancer History®

## **3<sup>rd</sup> International Merkel Cell Carcinoma Conference**

### **Day 1: Friday, May 3, 2024**

<b>0700 - 0750</b>	Registration Check-In / Breakfast
<b>0750 - 0800</b>	Welcome Address, House Keeping Items, Goals and Expectations Michael Wong, MD, PhD
<b>0800 - 0830</b>	<b>Keynote Address: The Merkel Cell Carcinoma Landscape</b> Paul Nghiem, MD, PhD
<b>Session I</b> <b>0830 - 1000</b>	<b>Polyoma Virus in Merkel Cell Carcinoma</b> <b>Session Leader and Moderator:</b> James DeCaprio, MD
0830 – 0845	<b>Contributions of Merkel Cell Polyomavirus to Merkel Cell Carcinoma</b> James DeCaprio, MD
0845 - 0900	<b>MCC Insights from Whole Genome Sequencing</b> Gabe Starrett, PhD
0900 - 0915	<b>Mouse Model of Virus-Positive MCC</b> Andrzej Dlugosz, MD
0915 - 0930	<b>ALTO Downregulates NFkB</b> Denise Galloway, PhD
0930 - 0945	<b>MCPyV Infection in Skin Organoids</b> Silvia Albertini, PhD
0945- 1000	<b>Q&amp;A with Speakers Panel</b>
1000 – 1015	Morning Break and Networking
<b>Session II</b> <b>1015 – 1200</b>	<b>Targeting Molecular Pathways in MCC</b> <b>Session Leader and Moderator:</b> Isaac Brownell, MD, PhD
1015 - 1030	<b>Practical Perspective on the Discovery and Validation of MCC Therapeutic Targets</b> Isaac Brownell, MD, PhD
1030 - 1045	<b>Discovery and Disruption of Core Regulatory Transcription Factors in Merkel Cell Carcinoma</b> Berkley Gryder, PhD
1045 - 1100	<b>Targeting the DNA Replication (ATR) Checkpoint to Overcome Immunotherapy Resistance in Merkel Cell Carcinoma</b> Rashmi Bhakuni, PhD
1100 – 1115	<b>Targeting MDM2 in p53 Wildtype MCC – Rational and What Was Learned from the Navtemadlin Trial</b> Michael Wong, MD, PhD
1115 - 1130	<b>DNA Methylation: An Epigenetic Chink in the Armor of Merkel Cell Carcinoma</b> Paul Harms, MD, PhD
1130 - 1145	<b>Q&amp;A with Speakers Panel</b>
1145 – 1205	<b>T Antigen–Specific CD8+ T Cells Associate with PD-1 Blockade Response in Virus-Positive Merkel Cell Carcinoma</b> Sine Reker Hadrup, PhD
1205 - 1215	<b>Q&amp;A</b>

1215 – 1300	Lunch will be Provided
<b>Session III</b> 1300 – 1445	<b>Immunobiology of MCC</b> <b>Session Leader and Moderator:</b> Shailender Bhatia, MD
1300 – 1310	<b>Introduction</b> Shailender Bhatia, MD
1310 – 1320	<b>Emerging Biomarkers of Response to PD-1 Blockade</b> Thomas Pulliam, MD, PhD Student
1320 - 1330	<b>Optimal Duration of Anti-PD-(L)1 Immunotherapy</b> Natalie Miller, MD, PhD
1330 - 1340	<b>Updates on Intra-Tumoral Immunotherapy</b> Andrew Brohl, MD
1340 - 1350	<b>Should Ipilimumab Be the New “Standard” for Refractory MCC?</b> David Miller, MD
1350 - 1400	<b>Immunotherapy in Organ Transplant Recipients</b> Ann Silk, MD
1400 - 1430	<b>Q&amp;A with Speakers Panel</b>
1430 - 1445	Afternoon Break and Networking
<b>Session IV</b> 1445 -1615	<b>Pathology Insights into MCC Biology</b> <b>Session Leader and Moderator:</b> Kenneth Tsai, MD, PhD
1445 – 1500	<b>Perspective on the Pathophysiology of MCC</b> Kenneth Tsai, MD, PhD
1500 – 1515	<b>Resident CD8 and Vδ1 T Cells Functionally Converge to Drive Anti-Tumor Response in Merkel Cell Carcinoma</b> Zachary Reinstein, BS, [PhD]
1515 – 1530	<b>The Current State of Diagnostic, Prognostic, and Predictive Markers for Merkel Cell Carcinoma.</b> Paul Harms, MD
1530 – 1545	<b>Tumor Cell-Intrinsic PD-1 Promotes Merkel Cell Carcinoma Growth via mTOR-Mitochondrial ROS Signaling</b> Tobias Schatton, PharmD, PhD
1545 – 1600	<b>Combined Tumours as a Clue to Understand MCC Biology</b> Thibault Kervarrec, PhD
1600 – 1615	<b>Q&amp;A with Speaker’s Panel</b>
<b>Session V</b> 1615 – 1715	<b>Cellular Therapy: Coming of Age for Solid Tumors and MCC</b> <b>Session Leader and Moderator:</b> Vernon Sondak, MD
1615 - 1625	<b>Surgical Perspective on Cellular Therapy for MCC</b> Vernon Sondak, MD
1625 – 1645	<b>May the Fourth Be with You: Cellular Therapy, Attack of the Clones</b> Cassian Yee, MD
1645 – 1700	<b>BPXR1030: An Autologous Engineered T-Cell CAR Targeting GPC3 in MCC</b> Ecaterina Dumbrava, MD
1700 - 1715	<b>Q&amp;A with Speaker’s Panel</b>
1715 - 1730	<b>Poster Session</b>

1730 – 1900	Welcome Reception/Dinner – Texas Themed
-------------	---

## Day 2: Saturday, May 4, 2024

0700 - 0800	Breakfast
0800 - 0810	<b>Day 1 Highlights and Expectations for Day 2</b> Michael Wong, MD, PhD
0810 – 0830	<b>Updates on the Radiation Therapy of MCC</b> Devarati Mitra, MD PhD
0830 - 0835	<b>Q&amp;A</b>
0835 – 0855	<b>How to Evaluate and Report Treatment Response After Adjuvant or Neo-Adjuvant Therapy</b> Victor G. Prieto MD PhD
0855 - 0900	<b>Q&amp;A -</b>
0900 - 0915	Morning Break and Networking
<b>Session VI</b>	<b>The Multidisciplinary Approach to MCC Diagnosis, Treatment and Follow up</b> <b>PANEL DISCUSSION: Discussion Based on Real Life Cases</b> <b>Moderators:</b> Merrick Ross, MD and Michael Wong, MD, PhD
0915 - 1115	<b>Panelists:</b> Drs. Paul Harms, PhD, David Miller, MD, Devarati Mitra, MD, PhD, Natalie Miller, MD, PhD, Vernon Sondak, MD, Sunandana Chandra, MD
	<b>HOT TOPICS</b>
0915 – 0935	• <b>Neoadjuvant Therapy – Who, What, When &amp; How?</b>
0935 – 0955	• <b>Surgical Approach – How Much is Enough? Biopsy Lymph Nodes?</b>
0955 – 1015	• <b>Adjuvant therapy – the New Standard for Everyone?</b>
1015 – 1035	• <b>Radiation Therapy – Cure, Palliation, Adjunctive</b>
1035 – 1055	• <b>Advanced Disease – PD-1 Monotherapy or with Anti-CTLA4 or Others</b>
1055 – 1115	• <b>Summary / Conclusion</b>
1115 - 1130	Morning Break and Networking
1130 - 1200	<b>PANEL DISCUSSION</b> <b>Moderator:</b> Paul Nghiem, MD PhD <b>Panelists:</b> Drs. Shailender Bhatia, MD, Andrew Brohl, MD, Isaac Brownell, MD, PhD, James DeCaprio MD, Kelly Harms, MD, Merrick Ross MD, Ken Tsai MD PhD
	<b>Unmet Needs and Knowledge Gaps – What Are We Doing on Monday?</b> <b>Clinical Trials: The “Art of the Possible” in a Rare Disease</b>
1200 – 1210	<b>Concluding Remarks – Meeting Adjournment</b> Michael Wong, MD, PhD
1210	Meeting Ends – Grab & Go Lunches